Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 20/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 6/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.61 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.61 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.61 |
| ▸ | RET | P07949 | 1/20 | 0.61 |
| ▸ | HCK | P08631 | 1/20 | 0.61 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.61 |
| ▸ | FLT4 | P35916 | 1/20 | 0.61 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.61 |
| ▸ | SIK1 | P57059 | 1/20 | 0.61 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.61 |
| ▸ | WNK3 | Q9BYP7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2485592 | 0.89 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL13273318 | 0.89 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL407996 | 0.86 | AURKA (0.58) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL2486741 | 0.81 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL10139772 | 0.80 | AURKA (0.62) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL13273257 | 0.80 | AURKA (1.00) | AURKAAURKBMAPK13CHEK2NTRK1 | |
| SCHEMBL408411 | 0.80 | AURKA (0.62) | AURKAAURKB | |
| SCHEMBL408777 | 0.78 | AURKA (0.50) | AURKAAURKB | |
| SCHEMBL407221 | 0.78 | AURKA (0.50) | AURKA | |
| SCHEMBL405825 | 0.77 | PTK6 (0.55) | AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | claimed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | claimed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | claimed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | claimed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | claimed |
| EP-2367822-B1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2016-10-05 | — | — | EP | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-8853391-B2 | Tricyclic azaindoles | MERCK PATENT GMBH (DE) | 2014-10-07 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| US-20120022060-A1 | Tricyclic Azaindoles | MERCK PATENT GMBH (DE) | 2012-01-26 | — | — | US | disclosed |
| EP-2367822-A1 | TRICYCLIC AZAINDOLES | Merck Patent GmbH (DE) | 2011-09-28 | — | — | EP | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
| WO-2010080253-A1 | TRICYCLIC AZAINDOLES | MERCK PATENT GMBH (DE) | 2010-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022060-A1 | Tricyclic Azaindoles | AZI2, DCK, PPP2CA | AURKA 515/4885AURKB 340/4885MAPK13 239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.